BGB-1663
- Generic Name
- BGB-1663
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 500
- Registration Number
- NCT06973187
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2025-05-14
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 150
- Registration Number
- NCT06970743
Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2025-04-02
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 30
- Registration Number
- NCT06906809
- Locations
- 🇺🇸
Fortrea Clinical Research Unit Inc, Madison, Wisconsin, United States
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Conditions
- CLLChronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2025-02-26
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 250
- Registration Number
- NCT06846671
- Locations
- 🇳🇿
North Shore Hospital, Auckland, New Zealand
🇺🇸Cleveland Clinic Florida, Weston, Florida, United States
🇺🇸Emory University Winship Cancer Institute, Atlanta, Georgia, United States
A Study of How [14C]-BGB-16673 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Participants
- First Posted Date
- 2025-01-15
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 8
- Registration Number
- NCT06776679
- Locations
- 🇺🇸
Fortrea Clinical Research Unit Inc, Madison, Wisconsin, United States
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
- Conditions
- B-cell MalignancyRelapsed CancerRefractory CancerB-cell Lymphoma
- Interventions
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 80
- Registration Number
- NCT06634589
- Locations
- 🇮🇹
Centroricerche Cliniche Di Verona Srl, Verona, Italy
🇺🇸Mayo Clinic Phoenix, Phoenix, Arizona, United States
🇺🇸University of Southern Californianorris Comprehensive, Los Angeles, California, United States
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
- Conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaWaldenström MacroglobulinemiaFollicular LymphomaNon-Hodgkin LymphomaMarginal Zone LymphomaMantle Cell LymphomaB-cell MalignancyRichter's TransformationDLBCL Unclassifiable
- Interventions
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 146
- Registration Number
- NCT05294731
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
🇨🇳Beijing Chao Yang Hospital,Capital Medical University, Beijing, Beijing, China
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
- Conditions
- Marginal Zone LymphomaChronic Lymphocytic LeukemiaDiffuse Large B Cell LymphomaB-cell MalignancySmall Lymphocytic LymphomaFollicular LymphomaWaldenström MacroglobulinemiaNon-Hodgkin LymphomaMantle Cell Lymphoma
- Interventions
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 621
- Registration Number
- NCT05006716
- Locations
- 🇫🇷
Hopital Estaing, Clermontferrand, France
🇫🇷Chu Henri Mondor, Creteil, France
🇫🇷Hopital Claude Huriez Chu Lille, Lille, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.